Quote:

---

Vertex pays $4.9 Billion for Alpine Immune Sciences...for its experimental drug Povetacicept... to treat igA Nephropathy, a kidney disease.

---

I thought Alpine must have other late stage drugs to make it worth that price. It doesn't. However Povetacicept could be used in a variety of other diseases, Povetacicept targets the BAFF/April pathway which involves differentiation of B-cells and their chemotaxis. It can decrease autoimmunity and inflammation to an extent. BAFF/APRIL needs activation of PI3K/AKT, NF-κB, and p38/MAPK pathways to work. Of course leronlimab downregulates it all and so much more.

It seems the scientists at Vertex are wholly unfamiliar with the CCR5 receptor or they would realize there are better options out there. Fortunately for Vertex, Cytodyn has so many other larger indications that need our attention that they can keep the igA Nephropathy indication to themselves.